Lo scompenso cardiaco da trastuzumab nel trattamento del tumore al seno

Translated title of the contribution: Trastuzumab-induced heart failure in the treatment of breast cancer

Luigi Tarantini, Mauro Feola, Adriana Albini, Stefania Gori, Jennifer Foglietta, Maria Antonietta Cicoira, Giovanni Pulignano

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The amplification of the HER receptor system is present in approximately 20% of breast cancers and confers a marked malignancy and a poor prognosis. Trastuzumab, a monoclonal antibody directed against the HER2 receptor, has dramatically improved the prognosis of patients with HER2+ metastatic and early breast cancer. However, the use of trastuzumab is associated with the possible development of myocardial dysfunction and heart failure. Trastuzumab-induced cardiac injury may be reversible, and a substantial proportion of patients can complete therapy. For this reason, careful monitoring of cardiac function, an aggressive treatment of hypertension and possibly the use of non-anthracycline-containing chemotherapy protocols are required during trastuzumab treatment. Owing to the selection of patients enrolled in major randomized trials, the safety profile of trastuzumab is currently unclear in elderly women, in patients at high cardiovascular risk and in those with structural heart disease on optimal treatment. Further studies are therefore needed to determine whether this highly effective therapy in breast cancer survival can be extended to such categories of patients.

Original languageItalian
JournalGiornale Italiano di Cardiologia
Volume13
Issue number5 SUPPL. 1
DOIs
Publication statusPublished - May 2012

Fingerprint

Heart Failure
Breast Neoplasms
Therapeutics
Patient Selection
Heart Diseases
Monoclonal Antibodies
Trastuzumab
Hypertension
Safety
Drug Therapy
Survival
Wounds and Injuries
Neoplasms

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Tarantini, L., Feola, M., Albini, A., Gori, S., Foglietta, J., Cicoira, M. A., & Pulignano, G. (2012). Lo scompenso cardiaco da trastuzumab nel trattamento del tumore al seno. Giornale Italiano di Cardiologia, 13(5 SUPPL. 1). https://doi.org/10.1714/1080.11830

Lo scompenso cardiaco da trastuzumab nel trattamento del tumore al seno. / Tarantini, Luigi; Feola, Mauro; Albini, Adriana; Gori, Stefania; Foglietta, Jennifer; Cicoira, Maria Antonietta; Pulignano, Giovanni.

In: Giornale Italiano di Cardiologia, Vol. 13, No. 5 SUPPL. 1, 05.2012.

Research output: Contribution to journalArticle

Tarantini, L, Feola, M, Albini, A, Gori, S, Foglietta, J, Cicoira, MA & Pulignano, G 2012, 'Lo scompenso cardiaco da trastuzumab nel trattamento del tumore al seno', Giornale Italiano di Cardiologia, vol. 13, no. 5 SUPPL. 1. https://doi.org/10.1714/1080.11830
Tarantini, Luigi ; Feola, Mauro ; Albini, Adriana ; Gori, Stefania ; Foglietta, Jennifer ; Cicoira, Maria Antonietta ; Pulignano, Giovanni. / Lo scompenso cardiaco da trastuzumab nel trattamento del tumore al seno. In: Giornale Italiano di Cardiologia. 2012 ; Vol. 13, No. 5 SUPPL. 1.
@article{ff8c21854cee44a5ab656bc1632b3560,
title = "Lo scompenso cardiaco da trastuzumab nel trattamento del tumore al seno",
abstract = "The amplification of the HER receptor system is present in approximately 20{\%} of breast cancers and confers a marked malignancy and a poor prognosis. Trastuzumab, a monoclonal antibody directed against the HER2 receptor, has dramatically improved the prognosis of patients with HER2+ metastatic and early breast cancer. However, the use of trastuzumab is associated with the possible development of myocardial dysfunction and heart failure. Trastuzumab-induced cardiac injury may be reversible, and a substantial proportion of patients can complete therapy. For this reason, careful monitoring of cardiac function, an aggressive treatment of hypertension and possibly the use of non-anthracycline-containing chemotherapy protocols are required during trastuzumab treatment. Owing to the selection of patients enrolled in major randomized trials, the safety profile of trastuzumab is currently unclear in elderly women, in patients at high cardiovascular risk and in those with structural heart disease on optimal treatment. Further studies are therefore needed to determine whether this highly effective therapy in breast cancer survival can be extended to such categories of patients.",
keywords = "Breast cancer, Heart failure, Trastuzumab",
author = "Luigi Tarantini and Mauro Feola and Adriana Albini and Stefania Gori and Jennifer Foglietta and Cicoira, {Maria Antonietta} and Giovanni Pulignano",
year = "2012",
month = "5",
doi = "10.1714/1080.11830",
language = "Italian",
volume = "13",
journal = "Giornale Italiano di Cardiologia",
issn = "1827-6806",
publisher = "CEPI s.r.l.",
number = "5 SUPPL. 1",

}

TY - JOUR

T1 - Lo scompenso cardiaco da trastuzumab nel trattamento del tumore al seno

AU - Tarantini, Luigi

AU - Feola, Mauro

AU - Albini, Adriana

AU - Gori, Stefania

AU - Foglietta, Jennifer

AU - Cicoira, Maria Antonietta

AU - Pulignano, Giovanni

PY - 2012/5

Y1 - 2012/5

N2 - The amplification of the HER receptor system is present in approximately 20% of breast cancers and confers a marked malignancy and a poor prognosis. Trastuzumab, a monoclonal antibody directed against the HER2 receptor, has dramatically improved the prognosis of patients with HER2+ metastatic and early breast cancer. However, the use of trastuzumab is associated with the possible development of myocardial dysfunction and heart failure. Trastuzumab-induced cardiac injury may be reversible, and a substantial proportion of patients can complete therapy. For this reason, careful monitoring of cardiac function, an aggressive treatment of hypertension and possibly the use of non-anthracycline-containing chemotherapy protocols are required during trastuzumab treatment. Owing to the selection of patients enrolled in major randomized trials, the safety profile of trastuzumab is currently unclear in elderly women, in patients at high cardiovascular risk and in those with structural heart disease on optimal treatment. Further studies are therefore needed to determine whether this highly effective therapy in breast cancer survival can be extended to such categories of patients.

AB - The amplification of the HER receptor system is present in approximately 20% of breast cancers and confers a marked malignancy and a poor prognosis. Trastuzumab, a monoclonal antibody directed against the HER2 receptor, has dramatically improved the prognosis of patients with HER2+ metastatic and early breast cancer. However, the use of trastuzumab is associated with the possible development of myocardial dysfunction and heart failure. Trastuzumab-induced cardiac injury may be reversible, and a substantial proportion of patients can complete therapy. For this reason, careful monitoring of cardiac function, an aggressive treatment of hypertension and possibly the use of non-anthracycline-containing chemotherapy protocols are required during trastuzumab treatment. Owing to the selection of patients enrolled in major randomized trials, the safety profile of trastuzumab is currently unclear in elderly women, in patients at high cardiovascular risk and in those with structural heart disease on optimal treatment. Further studies are therefore needed to determine whether this highly effective therapy in breast cancer survival can be extended to such categories of patients.

KW - Breast cancer

KW - Heart failure

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84867207314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867207314&partnerID=8YFLogxK

U2 - 10.1714/1080.11830

DO - 10.1714/1080.11830

M3 - Articolo

C2 - 23678535

AN - SCOPUS:84867207314

VL - 13

JO - Giornale Italiano di Cardiologia

JF - Giornale Italiano di Cardiologia

SN - 1827-6806

IS - 5 SUPPL. 1

ER -